
India tightens semaglutide supply after Interpol flags counterfeit batches
The story in brief
India's drug regulator has directed state authorities to tighten surveillance of pharmaceutical supply chains after an Interpol alert flagged counterfeit semaglutide batches. The drug, approved for type 2 diabetes, weight management, and cardiovascular risk reduction, is now available as a generic in India following its patent expiry on 20 March 2026. Domestic producers are unaffected as long as they operate through authorized channels.